Psy180 - Uk Health Technology Assessment of Orphan Drugs for Rare Oncology Versus Rare Disease: Does Orphan Designation Make Any Difference in Hta Process?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2754
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy187 - The Quantity and Quality of Evidence Supporting European Marketing Authorisation of Orphan Drugs: Comparison of Rare Oncology Versus Rare Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php94 - Does the Orphan Designation Increase the Chances of Positive Hta Opinion in France, Germany and Uk?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Hta Studies on Orphan Drugs by Rebratsxmembers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Orphan Designation: Trientine Dihydrochloride, Treatment of Wilson's Disease

Case Medical Research
2019English

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

Payer Management and Pricing Dynamics for Non-Oncology Pharmacy Benefit Orphan Drugs for Rare Diseases in the United States Launched 2004-2014

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Orphan Designation: Brincidofovir, Treatment of Smallpox

Case Medical Research
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy